While not necessary, manufacturing and distribution (to institutions) are linked perocesses, all out of scope for IMM. When we get to that point, I'd be happy for a pharma to buy the rights, unless there is SIGNIFICANT financial benefit in it for IMM to do it on its own, but potential lack of experience in that division may also potentially dampen efficiency in delivering the drug to the institution/patient and subsequently, the revenue.
As an analogy, for those familiar with resources exploration is ususlly a different business/ball game to mining.
Ann: Immutep presents positive TACTI-mel melanoma trial data, page-114
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |